[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100396964":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":36,"centralContacts":41,"locations":50,"responsibleParty":68,"collaborators":10,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":10,"enrollmentInfo":82,"targetDuration":85,"studyType":86,"phases":10,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":53,"whyStopped":10,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Charles University, Czech Republic","OTHER",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"sepsis\u002Fseptic shock",null,"target population",[13,14,15],"Other: transcriptomics","Other: flow-cytometry","Other: cytokines",{"label":17,"type":10,"description":18,"interventionNames":19},"non-septic critically ill","demographically-matched control group",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"healthy control","control group",[13,14,15],[25,28,32],{"type":6,"name":26,"description":26,"armGroupLabels":27,"otherNames":10},"transcriptomics",[21,17,9],{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"flow-cytometry","peripheral blood myeloid cells and lymphocytes flow-cytometry",[21,17,9],{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":10},"cytokines","peripheral blood cytokine analysis",[21,17,9],[37],{"name":38,"affiliation":39,"role":40},"Thomas Karvunidis, MD, PhD","Carles University Teaching Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic","PRINCIPAL_INVESTIGATOR",[42,47],{"name":43,"role":44,"phone":45,"phoneExt":10,"email":46},"Thomas Karvunidis, MD, Ph.D.","CONTACT","+420 377 103 173","karvunidist@fnplzen.cz",{"name":48,"role":44,"phone":45,"phoneExt":10,"email":49},"Marcela Královcová, MD","kralovcovam@fnplzen.cz",[51],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":10,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Medical ICU, 1st Dept. of Internal Medicine, Teaching Hospital in Pilsen","RECRUITING","Pilsen","Česká Republika","330 01","Czechia",{"type":59,"coordinates":60},"Point",[61,62],13.37759,49.74747,{"lat":62,"lon":61},[65,66],{"name":43,"role":44,"phone":45,"phoneExt":10,"email":46},{"name":67,"role":44,"phone":45,"phoneExt":10,"email":49},"Marcela Kralovcova, MD",{"type":40,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Thomas Karvunidis","Principal investigator","100396964","immune-homeostasis-in-sepsis-and-septic-shock-100396964",false,"NCT04448951","Immune Homeostasis in Sepsis and Septic Shock","Immune Homeostasis in Patients With Sepsis and Septic Shock: a Single Center Observational Study","IMHOTEP","Inclusion Criteria:\n\n* sepsis\u002Fseptic shock (SEPSIS-3)\n* age ≥18\n* informed consent\n* inclusion within first 24hrs after development\u002Fdiagnosis of septic shock\n\nExclusion Criteria:\n\n* disagreement of the patient or legal representative with the entry into the study\n* patients with primary or secondary immunodeficiency\n* presence of active haematological malignancy or an active non-haematological malignancy",true,"ALL","18 Years",{"count":83,"type":84},200,"ESTIMATED","90 Days","OBSERVATIONAL","Detailed description of immune response and its dynamics in sepsis and septic shock patiens by means of transcriptomics, flow-cytometry and cytokine analysis.",[89,90,91,92],"Sepsis","Immunologic Paralysis","Immunologic Suppression","Immune Deficiency",[94,95,96,97,26,29,98],"sepsis","septic shock","immune response","immunoparalysis","immunomodulation","2024-08-20",{"date":101,"type":102},"2024-08-21","ACTUAL",{"date":104,"type":102},"2020-09-01",{"date":106,"type":84},"2027-12-31",{"name":5,"class":6},1]